Midatech Pharma PLC (MTP)
|Net Income (ttm)||-13.27M|
|Trading Day||February 26|
|Day's Range||2.20 - 2.49|
|52-Week Range||0.86 - 7.07|
Midatech Pharma (MTP) news for Monday includes positive results from a Phase I study of a DIPG treatment boosting MTP stock higher. The post Midatech Pharma News: Why MTP Stock Is Surging 10% ...
Midatech Pharma plc (MTP) CEO Craig Cook on Q2 2020 Results - Earnings Call Transcript
Midatech Pharma (MTP) news for Friday includes talk from the company about reselling roughly 12.7 million shares pushing MTP stock higher. The post Midatech Pharma News: Why MTP Stock Is Soari...
Midatech Pharma (MTP) news for Tuesday concerning a collaboration deal involving the Q-Sphera platform has MTP stock taking off. The post Midatech Pharma News: Why MTP Stock Is Skyrocketing 15...
A stronger diabetes vaccine may be what the doctor will order soon as Midatech Pharma's clinical trial were "positive." MTP stock is up.
Midatech Pharma PLC-ADR (NASDAQ: MTP) shares were trading higher Friday after the company announced positive results from a first-in-human study of its MTX102 immuno-tolerizing vaccine product...
The U.S.-listed shares of Midatech Pharma PLC rocketed 113% on very heavy volume in premarket trading Friday.
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTD201, a long acting dose of Octreotide for the treatment of acromegaly and neuroendocrine tumors; and MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma. It also offers drug delivery platforms, such as Q-Sphera, a microencapsulation and polymer-depot sustained release drug delivery platform; MidaSolve, an oligosaccharide nanotechnology used... [Read more...]
Stephen A. Stamp
|Stock Exchange |
|Ticker Symbol |
In 2019, MTP's revenue was 674,000, a decrease of -65.22% compared to the previous year's 1.94 million. Losses were -10.09 million, -32.90% less than in 2018.